🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Thank you to Damian Green (Sylvester Comprehensive Cancer Center) & Rachid Baz (Moffitt Cancer Center) for discussing updates with the use of bispecifics and CAR T-cells in myeloma, highlighting important takeaways for community oncologists. What a great end to #iwMyeloma25! Keep an eye out for more on

Why has the development of effective immunotherapies for AML been challenging, and what potential do CAR-CIK cells hold for the treatment of this malignancy? Watch our fantastic interview with Andrea Biondi of Università degli Studi di Milano-Bicocca from #EBMT25 to find out: 🎥 ow.ly/7VPo50VxytT #AMLsm

Save the date! 🗓️ Next month, we’ll be in Paris for #IPIG2025, covering the latest advancements in #PNH. Be sure to follow us for all the updates! #RareDiseases

📣 Interested in hearing the EBMT consensus guidelines for alloSCT in T-cell #lymphoma? We are pleased to bring you an interview from #EBMT2025 in which Gandhi Damaj provided valuable insight into these guidelines! Watch here: 👉 ow.ly/3lE350Vy0ni #LYMsm #BMTsm The EBMT

🎥 Jan Schröder of Uniklinikum Tübingen shares the rationale behind developing a project aimed at studying the impact of prior B-cell directed immunotherapy on the outcomes of CD19 #CARTCell therapy in patients with aggressive B-cell malignancies: 👉 ow.ly/90HA50Vy0x6 #EBMT25

Check out this engaging discussion with experts Barbara Eichhorst (Universität zu Köln), Lydia Scarfò & Anna Schuh, who share updates to the ESMO CLL clinical practice guidelines & implications for frontline treatment: 👉ow.ly/j3Nq50VwqEc #CLLsm #LeuSM #HemOnc

Check out our latest podcast on sequencing therapies in R/R NHL🩸✨ Featuring Paolo Strati (MD Anderson Cancer Center), Manali Kamdar (manalikamdar), and Gloria Iacoboni (Gloria Iacoboni)! 🎧Listen here: ow.ly/jlra50VzYGr #LYMsm #HemOnc #NonHodgkinLymphoma

We were so happy that Valeria Santini of Università di Firenze stopped by to speak with us at the #EBMT25 meeting!😄 Watch the interview to hear Dr Santini discuss the importance of stratifying patients with MDS to optimize alloSCT outcomes: 🎥 ow.ly/28Lf50Vxztx #MDSsm #BMTsm

Don't forget to watch our recent interview with Cristina Papayannidis of Università di Bologna to hear about the ongoing research and unmet needs in #BPDCN. Click here: 👉 ow.ly/9PHA50VxYyI 👈 #RareDisease #ISAL2025 #HemOnc

🚨 Catch the latest expert insights from #EBMT25 on VJHemOnc.com! From updates in the field of transplantation to cutting-edge cell therapy, we’ve got you covered!🩸 🎥 Watch now: 👉 ow.ly/PHAQ50VvzZY #BMTsm #HemOnc #ImmunoOnc #CARTCell #Leusm #LYMsm The EBMT

It was a pleasure to interview Steven Devine of NMDP recently to hear the findings of a CIBMTR retrospective analysis investigating outcomes by donor type in patients undergoing transplantation with PTCy as GvHD prophylaxis: 👉 ow.ly/7iLq50VxyHB #EBMT25 #BMTsm

Today is World Hemophilia Day!🌏🩸 This year's theme is “Access for all: Women & girls bleed too”.👩👧 Join the bleeding disorders community in raising awareness for people with #Hemophilia, and check out our hemophilia channel: 👉 ow.ly/RT4Z50VhaSt #WHD2025 #WeBleedToo

#WHD2025 | What are the current approaches to prophylaxis in #hemophilia, and how should treatment be individualized?🩸 This World Hemophilia Day, check out our recent interview with Dr Amy Shapiro (IU School of Medicine) to find out: 🎥 ow.ly/tFPK50Vhb6G #WeBleedToo #Hematology

What are the rescue strategies available for patients with #myelofibrosis who experience treatment failure after transplantation? We caught up with Francesco Passamonti of Università degli Studi di Milano at #EBMT25 to bring you valuable insight into this: 👉 ow.ly/RxLR50VxAeG #MPNsm #BMTsm

🚨 New podcast alert! 🚨 Catch the key highlights from #EBMT25 — from preventing & managing GvHD to harnessing AI in transplant, and more. 🎧 Tune in now: ow.ly/izn250VCha2 #BMTsm #HemOnc

Is there cause for concern regarding the development of T-cell malignancy after #CARTCell therapy? Do the benefits of the treatment outweigh the risks? 💉🩸 Find out in our interview from #EBMT25 with Rémy Duléry (Dana-Farber): 🎥 ow.ly/YaVs50Vy0UP #ImmunoOnc The EBMT

In the future, artificial intelligence may play a role in personalized medicine for individuals with clonal hematopoiesis. Hear more from Matteo Della Porta of Humanitas Milano: 👉 ow.ly/w7VZ50VxXkY #MDSsm #HemOnc #AMLsm #IBC2025

It's always a pleasure to catch up with Maria Domenica Cappellini (Università degli Studi di Milano) to hear the latest in #SickleCellDisease & #thalassemia!🩸 Watch our interview from #ESHERYTHRO2025 for updates on recent advances in these hemoglobinopathies: 👉 ow.ly/mmcj50VuySt #SickleCell

At #EBMT25, the lovely Dr. Rawad Rihani of مؤسسة ومركز الحسين للسرطان presented the findings of a comprehensive analysis exploring the determinants & outcomes of graft failure in pediatric patients undergoing SCT for non-malignant disorders. Watch here: 👉 ow.ly/hrGU50Vy0H1 #BMTsm The EBMT

The #IPIG2025 meeting is only a few weeks away! We'll be filming interviews with #PNH experts and sharing the latest updates in the field - don't miss out🎥 Follow us for more!